share_log

福安药业(300194.SZ):全资子公司原料药苯唑西林钠获批上市

fuan pharmaceutical(300194.SZ):全額子会社医薬品有効成分ベンゾジアゼピンナトリウムが承認され上場

Gelonghui Finance ·  11/12 03:29

fuan pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, fuan pharmaceutical group's Chongqing Bosheng Pharmaceutical Co., Ltd. (referred to as "Bosheng Pharmaceutical"), recently received approval from the National Medical Products Administration to market application for chemical raw materials. The raw material is benzylpenicillin sodium, mainly used for various infections caused by penicillin-resistant staphylococcus aureus, including sepsis, respiratory tract infections, meningitis, soft tissue infections, and can also be used for mixed infections caused by pyogenic streptococcus or pneumococcus and penicillin-resistant staphylococcus.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする